前列腺穿刺后行经尿道前列腺铥激光剜除术的安全性与临床疗效分析

杨可豪, 刘志福, 卢强, 陈佳, 杨勇军, 宋光庆, 李远伟

湖南师范大学学报医学版 ›› 2026, Vol. 23 ›› Issue (2) : 99-105.

PDF(2312 KB)
PDF(2312 KB)
湖南师范大学学报医学版 ›› 2026, Vol. 23 ›› Issue (2) : 99-105.
临床医学

前列腺穿刺后行经尿道前列腺铥激光剜除术的安全性与临床疗效分析

  • 杨可豪#, 刘志福#, 卢强, 陈佳, 杨勇军, 宋光庆, 李远伟
作者信息 +

Analysis of the Safety and Clinical Efficacy of Transurethral Thulium Laser Enucleation of the Prostate Following Prostate Biopsy

  • YANG Kehao, LIU Zhifu, LU Qiang, CHEN Jia, YANG Yongjun, SONG Guangqing, LI Yuanwei
Author information +
文章历史 +

摘要

目的 评估术前前列腺穿刺活检(prostate biopsy,PB)对经尿道前列腺铥激光剜除手术(transurethral thulium laser prostatectomy,ThuLEP)的安全性和临床疗效的影响。方法 回顾性分析2022年1月—2025年9月病理证实为于湖南省人民医院接受ThuLEP的良性前列腺增生(benign prostatic hyperplasia,BPH)116名患者的临床数据。研究组(PB+BPH组,58例)为ThuLEP术前1~4周内接受过PB的患者。对照组(BPH组,58例)为经倾向性评分匹配(propensity score matching,PSM)控制混杂偏倚后的常规ThuLEP患者。PB+BPH组中根据穿刺活检与手术间隔时间分为<2周组与≥2周组。收集并分析围术期资料,评估手术的安全性和临床疗效。结果 术前资料显示,两组在血常规、血脂及慢性基础疾病方面差异无统计学意义;研究组(PB+BPH组)前列腺特异性抗原(prostate-specific antigen,PSA)相关指标均高于BPH组,差异均有统计学意义(均P<0.001),且前列腺影像报告和数据系统(prostate imaging reporting and data system,PI-RADS)评分分布差异有统计学意义(χ2=25.532,P<0.001)。术后资料显示,两组血常规、置管时间、住院时间及并发症差异均无统计学意义;PB+BPH组手术时间长于BPH组,差异有统计学意义(P<0.01)。随访结果显示,两组术后国际前列腺症状评分(international prostate symptom score,IPSS)与生活质量(quality of life,QoL)评分均较术前改善,但PB+BPH组术后1个月及3个月IPSS与QoL评分均高于BPH组。穿刺至手术时间间隔<2周者较≥2周者术后炎症反应更明显,表现为白细胞计数及中性粒细胞百分率升高,且手术时间更长,差异均有统计学意义(均P<0.05)。结论 术前1~4周内PB对ThuLEP的手术疗效与并发症发生率无明显影响,但其排尿症状改善所需要的时间略长于BPH组。

Abstract

Objective To evaluate the impact of preoperative prostate biopsy (PB) on the safety and clinical efficacy of transurethral thulium laser enucleation of the prostate (ThuLEP). Methods Retrospectively analyzed the clinical data of 116 patients with pathologically confirmed benign prostatic hyperplasia who underwent ThuLEP for benign prostatic hyperplasia (BPH) at Hunan Provincial People's Hospital from January 2022 to September 2025. The study group (PB+BPH, n=58) comprised patients who had undergone PB within 1-4 weeks prior to ThuLEP. The control group (BPH, n=58) consisted of routine ThuLEP patients after propensity score matching (PSM) to minimize confounding bias. Within the PB+BPH cohort, patients were further stratified by the interval between biopsy and surgery (<2 weeks vs ≥2 weeks). Perioperative variables were collected and analyzed to assess surgical safety and clinical outcomes. Results Preoperative data showed no significant differences between the two groups in routine blood tests, blood lipids, or chronic underlying diseases. Prostate-specific antigen (PSA) -related indicators were significantly higher in the prostate biopsy plus benign prostatic hyperplasia (PB+BPH) group than in the benign prostatic hyperplasia (BPH) group (all P<0.001), and the distribution of Prostate Imaging Reporting and Data System (PI-RADS) scores also differed significantly (χ2=25.532, P<0.001). Postoperatively, there were no significant differences between the two groups in routine blood tests, duration of catheterization, length of hospital stay, or complications, but the operative time was significantly longer in the PB+BPH group (P<0.01). Follow-up results showed that the International Prostate Symptom Score (IPSS) and quality of life (QoL) scores improved postoperatively in both groups; however, the PB+BPH group had higher IPSS and QoL scores than the BPH group at 1 and 3 months after surgery. Stratified analysis by the interval between prostate biopsy and surgery showed that patients with an interval of<2 weeks had more obvious postoperative inflammatory responses than those with an interval of ≥2 weeks, as manifested by elevated white blood cell counts and neutrophil percentages, as well as longer operative time (all P<0.05). Conclusion Prostate biopsy performed within 1-4 weeks before ThuLEP does not appear to adversely affect perioperative safety, overall surgical efficacy, or complication rates; however, postoperative improvement in voiding symptoms may take slightly longer compared with patients undergoing ThuLEP for BPH without a recent biopsy.

关键词

良性前列腺增生 / 前列腺穿刺 / 激光手术 / 疗效

Key words

benign prostatic hyperplasia / prostate biopsy / laser surgery / efficacy

引用本文

导出引用
杨可豪, 刘志福, 卢强, 陈佳, 杨勇军, 宋光庆, 李远伟. 前列腺穿刺后行经尿道前列腺铥激光剜除术的安全性与临床疗效分析[J]. 湖南师范大学学报医学版. 2026, 23(2): 99-105
YANG Kehao, LIU Zhifu, LU Qiang, CHEN Jia, YANG Yongjun, SONG Guangqing, LI Yuanwei. Analysis of the Safety and Clinical Efficacy of Transurethral Thulium Laser Enucleation of the Prostate Following Prostate Biopsy[J]. Journal of Hunan Normal University(Medical Science). 2026, 23(2): 99-105
中图分类号: R697.32   

参考文献

[1] EGAN KB.The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates[J]. Urol Clin North Am, 2016, 43(3): 289-297.
[2] 中华医学会泌尿外科学分会激光学组, 微创学组, 尿控学组. 经尿道激光前列腺剜除术热点问题中国专家共识[J]. 中华泌尿外科杂志, 2024, 45(7): 489-496.
[3] WEI JT, CALHOUN E, JACOBSEN SJ.Urologic diseases in America project: benign prostatic hyperplasia[J]. J Urol, 2008, 179: S75-S80.
[4] LEE SWH, CHAN EMC, LAI YK.The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis[J]. Sci Rep, 2017, 7(1): 7984.
[5] BABOUDJIAN M, HASHIM H, BHATT N, et al.Summary paper on underactive bladder from the European Association of Urology guidelines on non-neurogenic male lower urinary tract symptoms[J]. Eur Urol, 2024, 86(3): 213-220.
[6] DEYIRMENDJIAN C, ELTERMAN D, CHUGHTAI B, et al.Surgical treatment options for benign prostatic obstruction: beyond prostate volume[J]. Curr Opin Urol, 2022, 32(1): 102-108.
[7] SNYPER NYF, PIKE J, EKWUEME K, et al.Selective biomarkers for inflammation and infection are associated with post-operative complications following transperineal template prostate biopsy (TTPB): a single-centre observational clinical pilot-study[J]. Eur J Med Res, 2022, 27(1): 187.
[8] TURKBEY B, ROSENKRANTZ AB, HAIDER MA, et al.Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2[J]. Eur Urol, 2019, 76(3): 340-351.
[9] GAME X, VINCENDEAU S, PALASCAK R, et al.Total and free serum prostate specific antigen levels during the first month of acute prostatitis[J]. Eur Urol, 2003, 43(6): 702-705.
[10] ALIASGARI M, SOLEIMANI M, HOSSEINI MOGHADDAM SM.The effect of acute urinary retention on serum prostate-specific antigen level[J]. Urol J, 2005, 2(2): 89-92.
[11] 李宏基, 赵晓龙, 胡伟, 等. 前列腺癌早期筛查风险预测模型的建立与验证研究[J]. 中国全科医学, 2024, 27(20): 2483-2490.
[12] LI GZ, MAN L, HUANG G, et al.The correlation of extent and grade of inflammation with serum PSA levels in patients with IV prostatitis[J]. Int Urol Nephrol, 2010, 43(2): 295-301.
[13] TAN YG, TEO JS, KUO TLC, et al.A systemic review and meta-analysis of transabdominal intravesical prostatic protrusion assessment in determining bladder outlet obstruction and unsuccessful trial without catheter[J]. Eur Urol Focus, 2022, 8(4): 1003-1014.
[14] TUNCEL A, UZUN B, ERUYAR T, et al.Do prostatic infarction, prostatic inflammation and prostate morphology play a role in acute urinary retention?[J]. Eur Urol, 2005, 48(2): 277-284.
[15] YILDIZ A, AKDEMIR S, ANIL H, et al.Safety and efficacy of high-powered holmium laser enucleation of the prostate within 1-3 weeks following prostate biopsy[J]. Urol Int, 2021, 105(9-10): 852-857.
[16] ETAFY MH, KATZ JE, GONZALGO MR, et al.Holmium laser enucleation of prostate within 6 weeks of transrectal ultrasound guided prostate biopsy is safe and effective[J]. Urology, 2021, 148: 88-92.
[17] CHOI SM, KANG CS, KIM DH, et al.Clinical outcome and safety of holmium laser prostate enucleation after transrectal prostate biopsies for benign prostatic hyperplasia[J]. Investig Clin Urol, 2024, 65(2): 148-156.
[18] BELL C, MOORE SL, GILL A, et al.Safety and efficacy of holmium laser enucleation of the prostate in patients with previous transperineal biopsy: outcomes from a dual-centre case-control study[J]. BMC Urol, 2019, 19(1): 97.
[19] 贾毅杰, 周广臣, 柳长坤. 经会阴前列腺穿刺活检术对短期内行钬激光前列腺剜除术安全性及有效性的影响[J]. 浙江医学, 2023, 45(9): 950-954.
[20] PIAZZA P, BIANCHI L, GIAMPAOLI M, et al.Short time delay between previous prostate biopsy for prostate cancer assessment and holmium laser enucleation of the prostate correlates with worse perioperative outcomes[J]. Eur Urol Focus, 2021, 8(2): 563-571.
[21] GRAVAS S, GACCI M, GRATZKE C, et al.Summary paper on the 2023 European association of urology guidelines on the management of non-neurogenic male lower urinary tract symptoms[J]. Eur Urol, 2023, 84(2): 207-222.
[22] HARTUNG FO, EGEN L, GRĖNE B, et al. Perioperative outcomes and complication rates in holmium laser enucleation of the prostate patients after prior prostate biopsy-does it really make a difference? a propensity score matched analysis[J]. J Endourol, 2024, 38(7): 675-681.
[23] ZAHOREC R.Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill[J]. Bratisl Lek Listy, 2001, 102(1): 5-14.
[24] GU T, LI J, CHEN T, et al.It is not the best option to perform transurethral enucleation of the prostate immediately after biopsy in patients with histological inflammation[J]. Front Surg, 2024, 11: 1390656.

基金

湖南省卫生健康委2023年度国家临床重点专科重大科研专项“精准穿刺活检技术体系下前列腺癌包膜外侵犯的预测与临床决策分析”(Z2023088)

PDF(2312 KB)

Accesses

Citation

Detail

段落导航
相关文章

/

〈 〉